Results 51 to 60 of about 423,879 (287)

Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort [PDF]

, 2017
Gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs).
Pérez Ruiz, Fernando
core   +2 more sources

Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound

Kidney & Blood Pressure Research, 2018
Current urate-lowering therapy (ULT) includes three direct acting drugs (allopurinol, febuxostat, Rasburicase) and at least four ‘indirect’ drugs with other important targets (canagliflozin, losartan, fenofibrate and sevelamer).
Davide Viggiano, Giuseppe Gigliotti, Gianfranco Vallone, Anna Giammarino, Michelangelo Nigro, Giovambattista Capasso   +5 more
doaj   +1 more source

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.

PLoS ONE, 2019
Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD).
Hee Jung Jeon, Jieun Oh, Dong Ho Shin
doaj   +1 more source

Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. [PDF]

Arthritis Res Ther, 2022
Objective Linked metabolic and cardiovascular comorbidities are prevalent in hyperuricemia and gout. For mechanistic insight into impact on inflammatory processes and cardiometabolic risk factors of xanthine oxidase inhibitor urate-lowering therapy (ULT)
Guma M, Dadpey B, Coras R, Mikuls TR, Hamilton B, Quehenberger O, Thorisdottir H, Bittleman D, Lauro K, Reilly SM, Liu-Bryan R, Terkeltaub R.   +11 more
europepmc   +2 more sources

Using serum urate as a validated surrogate end point for flares in patients with gout:protocol for a systematic review and meta-regression analysis [PDF]

, 2016
INTRODUCTION: Gout is the most common inflammatory arthritis in men over 40 years of age. Long-term urate-lowering therapy is considered a key strategy for effective gout management.
Birger Morillon, Melanie, Christensen, R, Dalbeth, N., Fransen, J., Lassere, M., Singh, J A, Stamp, L., Taylor, E W   +7 more
core   +2 more sources

Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate‐Lowering Therapy in Ontario, Canada

Arthritis care & research, 2023
To assess the proportion of, and factors associated with, older adults with gout receiving a serum urate (SUA) test after starting urate‐lowering therapy (ULT).
Timothy S. H. Kwok, B. Kuriya, G. Hawker, P. Li, Gregory Choy, J. Widdifield   +5 more
semanticscholar   +1 more source

The impact of urate-lowering therapy on kidney function (IMPULsKF)

Počki, 2017
The concept of trial launched in Ukraine in 2017 with POEM design and 36-months duration is presented. It aims to investigate the impact of two target levels of urate-lowering therapy caused by hyperuricemia on kidney function and chronic kidney disease (
D.D. Ivanov
doaj   +1 more source

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative [PDF]

, 2014
We aimed to develop evidence-based multinational recommendations for the diagnosis and management of gout. Using a formal voting process, a panel of 78 international rheumatologists developed 10 key clinical questions pertinent to the diagnosis and ...
Aletaha, Daniel, Andres, Mariano, Bijlsma, Johannes W., Bombardier, Claire, Branco, Jaime C., Buchbinder, Rachelle, Burgos-Vargas, Ruben, Carmona, Loreto, Catrina, Anca I., Edwards, Christopher J., Elewaut, Dirk, Falzon, Louise, Ferrari, Antonio J. L., Kiely, Patrick, Kydd, Alison S. R., Landewe, Robert B., Leeb, Burkhard F., Moi, John, Montecucco, Carlomaurizio, Mueller-Ladner, Ulf, Ostergaard, Mikkel, Seth, Rakhi, Sivera, Francisca, Sriranganathan, Melonie, van der Heijde, Desiree M., van Durme, Caroline, van Echteld, Irene, Vinik, Ophir, Wechalekar, Mihir D., Zochling, Jane   +29 more
core   +1 more source

Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial

Trials, 2023
Background Long-term gout treatment is based on reducing serum urate levels using urate-lowering therapy (ULT). Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a serum urate ...
I. R. Peeters, A. D. den Broeder, W. Taylor, N. den Broeder, M. Flendrie, N. van Herwaarden   +5 more
semanticscholar   +1 more source

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial

Arthritis Research & Therapy, 2022
Background Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent gout flares, functionally limiting tophi, and low quality of life.
John K. Botson, Katie Obermeyer, Brian LaMoreaux, Lin Zhao, Michael E. Weinblatt, Jeff Peterson   +5 more
doaj   +1 more source